Imperial College London
Portrait Picture

ProfessorMichaelLevin

Faculty of Medicine, Department of Infectious Disease

Chair in Paediatrics & International Child Health
 
 
 
//

Contact

 

+44 (0)20 7594 3760m.levin Website

 
 
//

Location

 

233Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Takele:2021:10.1101/2021.03.30.437646,
author = {Takele, Y and Mulaw, T and Adem, E and Shaw, CJ and Franssen, SU and Womersley, R and Kaforou, M and Taylor, GP and Levin, M and Müller, I and Cotton, JA and Kropf, P},
doi = {10.1101/2021.03.30.437646},
title = {Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV},
url = {http://dx.doi.org/10.1101/2021.03.30.437646},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>ABSTRACT</jats:title><jats:p>Visceral leishmaniasis (VL) has emerged as a clinically important opportunistic infection in HIV patients, as VL/HIV co-infected patients suffer from frequent VL relapse. Here, we followed cohorts of VL patients with or without HIV co-infections in Ethiopia and collected detailed clinical and immunological data during 12 months of follow-up. By the end of the study 78.1% of VL/HIV patients, but none of the VL only patients, had relapsed. Despite clinically defined cure, VL/HIV patients maintained high parasite loads, low BMI, hepatosplenomegaly and pancytopenia throughout follow-up. During detailed immunological study throughout the follow-up period, we identified three markers associated with VL relapse: i) failure to restore antigen-specific production of IFNγ, ii) persistently low CD4<jats:sup>+</jats:sup> T cell counts, and iii) high expression of PD1 on CD4<jats:sup>+</jats:sup> T cells. We show that these three markers combine well in predicting VL relapse, and that all three measurements are needed for optimal predictive power.</jats:p><jats:p>These three immunological markers can be measured in primary hospital settings in Ethiopia and can predict VL relapse after anti-leishmanial therapy. The use of our prediction model has the potential to improve disease management and patient care.</jats:p>
AU  - Takele,Y
AU  - Mulaw,T
AU  - Adem,E
AU  - Shaw,CJ
AU  - Franssen,SU
AU  - Womersley,R
AU  - Kaforou,M
AU  - Taylor,GP
AU  - Levin,M
AU  - Müller,I
AU  - Cotton,JA
AU  - Kropf,P
DO  - 10.1101/2021.03.30.437646
PY  - 2021///
TI  - Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV
UR  - http://dx.doi.org/10.1101/2021.03.30.437646
ER  -
Download